In summary, our study revealed that CD36 expression is decreased in TNBC and that higher CD36 expression correlates with improved prognosis in TNBC patients, suggesting that CD36 may function as a tumor suppressor in this subtype of breast cancer. This evidence concerns the gene CD36 and neoplasm.